The context
The COVID-19 pandemic created a global health emergency of unprecedented scale and urgency. The challenge was not only to develop effective vaccines at speed, but also to manufacture and distribute them globally under intense political, logistical and societal pressure.
The key opportunity and threat
- Opportunity – to save millions of lives and enable societies and economies to recover through rapid scientific and operational breakthrough
- Threat – fragmented efforts, regulatory delays, supply chain constraints, and public mistrust undermining speed and effectiveness
What they did that was special
An extraordinary level of cross-sector collaboration and innovation was mobilised at pace:
- Governments, pharmaceutical companies, regulators and academia aligned around a shared global mission
- Vaccine development, testing and approval processes were run in parallel rather than sequentially
- Significant upfront investment de-risked manufacturing before approvals were complete
- Global supply chains and cold-chain logistics were rapidly scaled and coordinated
- Transparent communication and real-time data sharing accelerated decision-making
For example…
During vaccine development, pharmaceutical companies began manufacturing doses before clinical trials were complete, something almost unheard of due to the financial risk. Governments underwrote this risk, enabling production to scale in parallel with testing.
At the same time, regulators conducted rolling reviews of trial data rather than waiting for final submissions, dramatically accelerating approval timelines. This combination of shared risk, parallel processing, and real-time collaboration cut years off the traditional vaccine timeline.
This resulted in vaccines being developed, approved and deployed in under a year, something previously thought impossible, saving millions of lives and demonstrating what can be achieved under extreme pressure
Shared mission – how clearly aligned are your stakeholders around a single, urgent goal, and what would improve that alignment?
Pace vs process – where are your processes sequential by default, and how could you safely run more activities in parallel?
Collaboration at scale – how effectively do you collaborate across organisational or sector boundaries, and what barriers exist today?
Risk appetite – where are you being overly cautious, and what calculated risks could unlock step-change progress?
Execution capability – how resilient and scalable are your delivery systems under pressure?
Ambition gap – if this level of pace and collaboration is possible in a crisis, what is realistically achievable in your organisation without such a crisis, and what is holding you back?